ArticleCNS drugs2018
Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database.
Article in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Agomelatine and the potential inverse risk of metabolic disorders: a nationwide cohort study with an active comparator design in Taiwan.Diabetology & metabolic syndrome · 2026Article
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- Sini San ameliorates symptoms of depression by modulating gut microbiota structure, Tryptophan metabolism, and short-chain fatty acid levels.BMC complementary medicine and therapies · 2025Article
- Use of oral fluoroquinolones in France between 2014 and 2023: a nationwide drug utilization study.JAC-antimicrobial resistance · 2025Article
- Personalized venlafaxine dose prediction using artificial intelligence technology: a retrospective analysis based on real-world data.International journal of clinical pharmacy · 2024Article
- Concomitant medication, comorbidity and survival in patients with breast cancer.Nature communications · 2024Article
- Sertraline induced acute hepatocellular liver injury in patient with major depressive disorder: a case report.Frontiers in psychiatry · 2024Article
- Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.Therapeutic advances in drug safety · 2024Article
- Tricyclic antidepressants induce liver inflammation by targeting NLRP3 inflammasome activation.Cell communication and signaling : CCS · 2023Article
- Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study.Scientific reports · 2023Article
- High-content imaging of human hepatic spheroids for researching the mechanism of duloxetine-induced hepatotoxicity.Cell death & disease · 2022Article
- The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity.Cell death discovery · 2022Article
- Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.Therapeutic advances in psychopharmacology · 2022Review
- Acute Hepatitis Due to Agomelatine Use in Elderly Women with Depression: Case Series.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- CYP1A2 polymorphism may contribute to agomelatine-induced acute liver injury: Case report and review of the literature.Medicine · 2021Review
- Antidepressants- and antipsychotics-induced hepatotoxicity.Archives of toxicology · 2021Review
- The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.Human psychopharmacology · 2021Observational
- Agomelatine Drug Utilisation Study in Selected European Countries: A Multinational, Observational Study to Assess Effectiveness of Risk-Minimisation Measures.Pharmaceutical medicine · 2019Observational
- Article
- Drug-Induced Liver Injury: Highlights of the Recent Literature.Drug safety · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatotoxicity may be a concern when prescribing antidepressants. Nevertheless, this risk remains poorly understood for serotonin and noradrenaline reuptake inhibitors (SNRIs: venlafaxine, milnacipran, duloxetine) and 'other antidepressants' (mianserin, mirtazapine, tianeptine and agomelatine), particularly in comparison with selective serotonin reuptake inhibitors (SSRIs: fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram), which are by far the most commonly prescribed antidepressants.
objectiveWe quantified the risk of serious liver injury associated with new use of SNRIs and 'other antidepressants' compared with SSRIs in real-life practice.
methodsBased on the French national health insurance database, this cohort study included 4,966,825 individuals aged 25 years and older with a first reimbursement of SSRIs, SNRIs or 'other antidepressants' between January 2010 and June 2015. We compared the risk of serious liver injury within the 6 months following antidepressant initiation according to antidepressant class, with SSRIs as the reference, using an inverse probability-of-treatment-weighted Cox proportional hazard model adjusted for demographic characteristics and risk factors of liver injury.
resultsWe identified 382 serious liver injuries overall (none for milnacipran initiators). Age and gender standardized incidence rates per 100,000 person-years were 19.2 for SSRIs, 22.2 for venlafaxine, 12.6 for duloxetine, 21.5 for mianserin, 32.8 for mirtazapine, 31.6 for tianeptine and 24.6 for agomelatine initiators. Initiation of antidepressants of interest versus SSRIs was not associated with an increased risk of serious liver injury [adjusted hazard ratios (95% confidence interval): venlafaxine 1.17 (0.83-1.64), duloxetine 0.54 (0.28-1.02), mianserin 0.90 (0.58-1.41), mirtazapine 1.17 (0.67-2.02), tianeptine 1.35 (0.82-2.23) and agomelatine 1.07 (0.51-2.23)]. This finding was confirmed by the results of an additional study using a case-time-control design.
conclusionThese results do not provide evidence of an increased risk of serious liver injury following initiation of SNRIs or 'other antidepressants' compared with SSRIs in real-life practice. This could reflect an inherent lack of difference in risk between the drug classes, or the fact that individuals with higher susceptibility to drug-induced liver injury are not prescribed drugs considered to be more hepatotoxic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.